Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SABINE pediatric IgA nephropathy trial
2024-518759-45-00Phase 3Authorised
- Sponsor
- Medical University of Warsaw
- Start
- Jun 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in IgA nephropathy (IgAN) comparing Entocort arm with Placebo arm (2 arms). Primary endpoints: Reduction of UPCR after 24 weeks of treatment and Percentage change in proteinuria at end of treatment. Planned start Jun 2025; status: authorised.
02
Drugs
budesonide
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on 2024-518759-45-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518759-45-00.